Quest Diagnostics (DGX) PT Raised to $226 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $251.82 --0%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Join SI Premium – FREE
Morgan Stanley analyst Erin Wright raised the price target on Quest Diagnostics (NYSE: DGX) to $226.00 (from $207.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Macquarie Upgrades Manila Electric Co. (MER:PM) (MAEOY) to Outperform
- Kia Motors (000270:KS) (KIMTF) PT Lowered to KRW200,000 at Macquarie
- I-TAIL Corp PCL (ITC:TB) PT Raised to THB23.30 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
